Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-Positive Anaplastic T Large Cell Lymphoma Treated with Crizotinib | Zendy

Carolina Mahuad | Zendy; Maria De Los Angeles Vicente Reparaz | Zendy; Marta Zerga | Zendy; María Florencia Aizpurua | Zendy; Claudia Casali | Zendy; Gonzalo Garate | Zendy

Open Access

Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-Positive Anaplastic T Large Cell Lymphoma Treated with Crizotinib

Author(s) -

Carolina Mahuad,

Maria De Los Angeles Vicente Reparaz,

Marta Zerga,

María Florencia Aizpurua,

Claudia Casali,

Gonzalo Garate

Publication year - 2016

Publication title -

rare tumors

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.285

H-Index - 15

eISSN - 2036-3613

pISSN - 2036-3605

DOI - 10.4081/rt.2016.6266

Subject(s) - crizotinib , anaplastic lymphoma kinase , medicine , anaplastic large cell lymphoma , refractory (planetary science) , lung cancer , alk inhibitor , lymphoma , cancer research , oncology , biology , astrobiology , malignant pleural effusion

The prognosis of the primary refractory anaplastic lymphoma kinase (ALK+) anaplastic T large cell lymphoma is ominous. The identification of molecular targets with potential to drive oncogenesis remains a cornerstone for the designing of new selective cancer therapies. Crizotinib is a selective ATP-competitive inhibitor for ALK, approved for its use in lung cancer with rearrangements on ALK gene. The reported cases describe the use of crizotinib as a bridging strategy prior to allotransplantation; there are no reported prolonged survivals under monotherapy with Crizotinib. We report a case of a primary refractory ALK+ anaplastic largecell lymphoma that sustains complete response after 3 years of crizotinib monotherapy

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research